These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 34666622)

  • 21. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates.
    Corbett KS; Gagne M; Wagner DA; O' Connell S; Narpala SR; Flebbe DR; Andrew SF; Davis RL; Flynn B; Johnston TS; Stringham CD; Lai L; Valentin D; Van Ry A; Flinchbaugh Z; Werner AP; Moliva JI; Sriparna M; O'Dell S; Schmidt SD; Tucker C; Choi A; Koch M; Bock KW; Minai M; Nagata BM; Alvarado GS; Henry AR; Laboune F; Schramm CA; Zhang Y; Yang ES; Wang L; Choe M; Boyoglu-Barnum S; Wei S; Lamb E; Nurmukhambetova ST; Provost SJ; Donaldson MM; Marquez J; Todd JM; Cook A; Dodson A; Pekosz A; Boritz E; Ploquin A; Doria-Rose N; Pessaint L; Andersen H; Foulds KE; Misasi J; Wu K; Carfi A; Nason MC; Mascola J; Moore IN; Edwards DK; Lewis MG; Suthar MS; Roederer M; McDermott A; Douek DC; Sullivan NJ; Graham BS; Seder RA
    Science; 2021 Dec; 374(6573):1343-1353. PubMed ID: 34672695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
    Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M
    N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337
    [No Abstract]   [Full Text] [Related]  

  • 23. Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2.
    Lustig Y; Nemet I; Kliker L; Zuckerman N; Yishai R; Alroy-Preis S; Mendelson E; Mandelboim M
    N Engl J Med; 2021 Jun; 384(25):2453-2454. PubMed ID: 33826815
    [No Abstract]   [Full Text] [Related]  

  • 24. The long road.
    Cohen J
    Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838
    [No Abstract]   [Full Text] [Related]  

  • 25. SARS-CoV-2 Antibody Response in Persons with Past Natural Infection.
    Anichini G; Terrosi C; Gandolfo C; Gori Savellini G; Fabrizi S; Miceli GB; Cusi MG
    N Engl J Med; 2021 Jul; 385(1):90-92. PubMed ID: 33852796
    [No Abstract]   [Full Text] [Related]  

  • 26. The overlooked superpower of mRNA vaccines.
    Wadman M
    Science; 2021 Jul; 373(6554):479. PubMed ID: 34326217
    [No Abstract]   [Full Text] [Related]  

  • 27. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.
    Liu Y; Liu J; Xia H; Zhang X; Zou J; Fontes-Garfias CR; Weaver SC; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
    N Engl J Med; 2021 Jul; 385(5):472-474. PubMed ID: 33979486
    [No Abstract]   [Full Text] [Related]  

  • 28. Neutralizing Activity of BNT162b2-Elicited Serum.
    Liu Y; Liu J; Xia H; Zhang X; Fontes-Garfias CR; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Weaver SC; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
    N Engl J Med; 2021 Apr; 384(15):1466-1468. PubMed ID: 33684280
    [No Abstract]   [Full Text] [Related]  

  • 29. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
    Wu K; Werner AP; Koch M; Choi A; Narayanan E; Stewart-Jones GBE; Colpitts T; Bennett H; Boyoglu-Barnum S; Shi W; Moliva JI; Sullivan NJ; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
    N Engl J Med; 2021 Apr; 384(15):1468-1470. PubMed ID: 33730471
    [No Abstract]   [Full Text] [Related]  

  • 30. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
    Zhou X; Wang H; Ji Q; Du M; Liang Y; Li H; Li F; Shang H; Zhu X; Wang W; Jiang L; Stepanov AV; Ma T; Gong N; Jia X; Gabibov AG; Lou Z; Lu Y; Guo Y; Zhang H; Yang X
    Protein Cell; 2021 Oct; 12(10):818-823. PubMed ID: 33909239
    [No Abstract]   [Full Text] [Related]  

  • 32. SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors.
    Frieman M; Harris AD; Herati RS; Krammer F; Mantovani A; Rescigno M; Sajadi MM; Simon V
    EBioMedicine; 2021 Jun; 68():103401. PubMed ID: 34051441
    [No Abstract]   [Full Text] [Related]  

  • 33. Audio Interview: How Well Are Covid-19 Vaccines Working?
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Jul; 385(2):e15. PubMed ID: 34233102
    [No Abstract]   [Full Text] [Related]  

  • 34. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
    Krammer F; Srivastava K; Alshammary H; Amoako AA; Awawda MH; Beach KF; Bermúdez-González MC; Bielak DA; Carreño JM; Chernet RL; Eaker LQ; Ferreri ED; Floda DL; Gleason CR; Hamburger JZ; Jiang K; Kleiner G; Jurczyszak D; Matthews JC; Mendez WA; Nabeel I; Mulder LCF; Raskin AJ; Russo KT; Salimbangon AT; Saksena M; Shin AS; Singh G; Sominsky LA; Stadlbauer D; Wajnberg A; Simon V
    N Engl J Med; 2021 Apr; 384(14):1372-1374. PubMed ID: 33691060
    [No Abstract]   [Full Text] [Related]  

  • 35. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
    Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
    Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2.
    Sapkal GN; Yadav PD; Ella R; Deshpande GR; Sahay RR; Gupta N; Vadrevu KM; Abraham P; Panda S; Bhargava B
    J Travel Med; 2021 Jun; 28(4):. PubMed ID: 33772577
    [No Abstract]   [Full Text] [Related]  

  • 38. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.
    Wang GL; Wang ZY; Duan LJ; Meng QC; Jiang MD; Cao J; Yao L; Zhu KL; Cao WC; Ma MJ
    N Engl J Med; 2021 Jun; 384(24):2354-2356. PubMed ID: 33822491
    [No Abstract]   [Full Text] [Related]  

  • 40. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
    Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Schmitt AM; Tippu Z; Farag S; Rogiers A; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Barber T; Emslie-Henry A; Caulfield-Lynch N; Byrne F; Shum B; Gerard CL; Deng D; Kjaer S; Song OR; Queval C; Kavanagh C; Wall EC; Carr EJ; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Shea RL; Gardner G; Murray D; Yousaf N; Jhanji S; Van As N; Young K; Furness AJS; Pickering L; Beale R; Swanton C; ; Gandhi S; Gamblin S; Bauer DLV; Kassiotis G; Howell M; Nicholson E; Walker S; Wilkinson RJ; Larkin J; Turajlic S;
    Cancer Cell; 2022 Feb; 40(2):114-116. PubMed ID: 34968417
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.